阿司匹林与他汀治疗非阻塞性冠心病:CONFIRM注册研究的五年结局
基于CONFIRM前瞻性队列研究,纳入6386例冠状动脉CT血管成像无斑块或非阻塞性(1%-49%狭窄)冠心病患者,平均随访5.66年。非阻塞性冠心病患者中,基线他汀使用与主要不良心血管事件风险降低相关(HR 0.59),而阿司匹林使用与结局无显著关联;无斑块者两种治疗均无获益。
要点
- 非阻塞性冠心病(1%-49%狭窄)患者全因死亡率10.6%,显著高于无冠心病者的4.8%(P < .001)。
- 非阻塞性冠心病患者中,基线他汀使用与主要不良心血管事件风险降低独立相关(HR 0.59)。
- 无斑块者中,阿司匹林或他汀使用均未改善临床结局。
核心结论
- 在非阻塞性冠心病患者中,基线他汀使用(而非阿司匹林)与临床结局改善相关;无斑块者两种治疗均无获益。
研究设计与样本
- 前瞻性队列研究,纳入CONFIRM国际多中心注册中6386例接受冠状动脉CT血管成像、无斑块或非阻塞性(1%-49%狭窄)冠心病患者,排除≥50%狭窄者;研究于2003年6月开始至2016年3月完成;采用Cox比例风险模型,医院站点以共享脆弱模型建模。
诊断标准与关键数值
- 非阻塞性冠心病定义为冠状动脉CT血管成像示1%-49%狭窄,阻塞性定义为≥50%狭窄并排除。
- 非阻塞性冠心病患者中,基线他汀使用与主要不良心血管事件风险降低相关(HR 0.59,95% CI 0.40-0.87,P = .007)。
- 非阻塞性冠心病患者中,基线阿司匹林使用与主要不良心血管事件无显著关联(10.9% vs 14.7%,P = .06)。
临床应用与阅片要点
- 冠状动脉CT血管成像发现非阻塞性冠心病(1%-49%狭窄)时,可提示临床关注他汀治疗的潜在获益。
- 无斑块者中阿司匹林或他汀均未显示获益,报告时不应据此推荐用药。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: In this cohort study, 5-year data from the Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter Registry (ie, CONFIRM) were examined to identify associations of baseline aspirin and statin use with mortality, major adverse cardiovascular events (MACE), and myocardial infarction (MI) in individuals without substantial (≥50%) stenosis.
MATERIALS AND METHODS: In this prospective cohort study, all participants in the registry underwent coronary CT angiography and were classified as having no detectable coronary plaque or having nonobstructive coronary artery disease (CAD) (1%-49% stenosis). Participants with obstructive (≥50%) stenosis were excluded from analysis. The study commenced in June 2003 and was completed in March 2016. All unadjusted and risk-adjusted analyses utilized the Cox proportional hazard model with hospital sites modeled using shared frailty.
RESULTS: A total of 6386 participants with no detectable plaque or with nonobstructive CAD were included (mean age, 56.0 years ± 13.3 [SD], 52% men). The mean follow-up period was 5.66 years ± 1.10. Nonobstructive CAD (n = 2815, 44% of all participants included in the study) was associated with a greater risk of all-cause mortality (10.6% [298 of 2815] vs 4.8% [170 of 3571], P < .001) compared to those without CAD (n = 3571, 56%). Baseline aspirin and statin use was documented for 1415 and 1429 participants, respectively, with nonobstructive CAD, and for 1560 and 1565 participants without detectable plaque, respectively. In individuals with nonobstructive CAD, baseline aspirin use was not associated with a reduction in MACE (10.9% [102 of 936] vs 14.7% [52 of 355], P = .06), all-cause mortality (9.6% [95 of 991] vs 10.9% [46 of 424], P = .468), or MI (4.4% [41 of 936] vs 6.2% [22 of 355], P = .18). On multivariate risk-adjusted analysis, baseline statin use was associated with a lower rate of MACE (hazard ratio, 0.59; 95% CI: 0.40, 0.87; P = .007). Neither therapy improved clinical outcomes for participants with no detectable plaque.
CONCLUSION: In participants with nonobstructive CAD, baseline use of statins, but not of aspirin, was associated with improved clinical outcomes. Neither therapy was associated with benefit in participants without plaque.Keywords: Aspirin, Statin, Coronary Artery Disease, CT Angiography, Nonobstructive Coronary Artery DiseaseClinical trial registration no. NCT01443637 Supplemental material is available for this article. © RSNA, 2022See also the commentary by Canan and Navar in this issue.
引用
- Indraratna, Naoum, Ben Zekry, et al. Aspirin and Statin Therapy for Nonobstructive Coronary Artery Disease: Five-year Outcomes from the CONFIRM Registry. Radiol Cardiothorac Imaging. 2022. PMID: 35506137. doi:10.1148/ryct.210225
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。